Month 3, week 14 (cagri 0.25 mg + reta 2 mg) New round of GI tolerability slow gastric emptying via amylin receptor stacks on top of GLP-1 slow gastric emptying Most community sources describe a "second nausea wave" lasting 57 days at the start of cagrilintide, milder than the original retatrutide titration Hunger between meals reportedly drops further amylin signaling is more meal-bound than GLP-1's sustained suppression Month 4 (cagri 0.5 mg + reta 2 mg) Stack feels stable Weight-loss rate may accelerate modestly compared with retatrutide-alone trajectory Community reports describe "smoother" appetite fewer rebound hunger episodes between meals Month 56 (cagri 1.01.7 mg + reta 2 mg) Approaching cagrilintide maintenance (2.4 mg/week is the Phase 3 dose) REDEFINE 1 analog data: this is the period where the cagrilintide+semaglutide arm pulled away from semaglutide alone Subjective effect: "the cagrilintide is working" reports cluster here Month 7+ (cagri 2.4 mg + reta 24 mg) Stack at maintenance Weight loss typically continues at a measurable rate, in line with retatrutide Phase 2 and REDEFINE 1 analog data Some community users titrate retatrutide higher (3 mg, 4 mg/week) at this point if tolerability permits Months 712 Stack at Maintenance This is the period where the stack's overall result accumulates
doi: 10.1111/j.1476-5381.2012.01971.x
Proc Natl Acad Sci U S A 76:268272 Gromes R, Hothorn M, Lenherr ED, Rybin V, Scheffzek K, Rausch T (2008a) The redox switch of gamma-glutamylcysteine ligase via a reversible monomer-dimer transition is a mechanism unique to plants
The bulk of the compelling evidence for BPC-157 comes from animal models, and it's genuinely impressive within that context
(2014) reported the role of AhR signalling in maintenance of Sertoli cell architecture and resultant spermatogenesis in AhR knockout mice where the poorly remodelled spermatozoa are suggested to be more susceptible to oxidant attack
